🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →
S&P 500: 661.43 -1.4% NASDAQ 100: 594.90 -1.4% Dow Jones: 463.00 -1.7%

Richard Pzena’s GSK Holdings & Trades

First Buy
Q2 2025
Duration Held
3 Quarters
Largest Add
Q2 2025
+7,510 Shares
Current Position
13,444 Shares
$659,292 Value

Richard Pzena's GSK Position Overview

Richard Pzena (via Pzena Investment Management LLC) currently holds 13,444 shares of GSK plc (GSK) worth $659,292, representing 0.00% of the portfolio. First purchased in 2025-Q2, this short-term holding has been held for 3 quarters.

Based on 13F filings, Richard Pzena has maintained this position in GSK for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2025, adding 4,727 shares.

Analysis based on 13F filings available since 2013 Q2

Richard Pzena's GSK plc (GSK) Holding Value Over Time

Track share changes against reported price movement

Quarterly GSK plc (GSK) Trades by Richard Pzena

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q4 2025 +4,727 Add 54.23% 13,444 $49.04
Q3 2025 +1,207 Add 16.07% 8,717 $43.16
Q2 2025 +7,510 New Buy 7,510 $38.40

Richard Pzena's GSK plc Investment FAQs

Richard Pzena first purchased GSK plc (GSK) in Q2 2025, acquiring 7,510 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Richard Pzena has held GSK plc (GSK) for 3 quarters since Q2 2025.

Richard Pzena's largest addition to GSK plc (GSK) was in Q2 2025, adding 7,510 shares worth $288,384.

According to the latest 13F filing for Q4 2025, Richard Pzena's firm, Pzena Investment Management LLC, owns 13,444 shares of GSK plc (GSK), valued at approximately $659,292.

As of the Q4 2025 filing, GSK plc (GSK) represents approximately 0.00% of Richard Pzena's publicly disclosed stock portfolio, making it one of their key holdings.

Richard Pzena's peak holding in GSK plc (GSK) was 13,444 shares, as reported at the end of Q4 2025.